Skip to content

Effects of GnRH Antagonist versus GnRH Agonist Protocol on ART outcomes in Poor ovarian Responders

Effects of GnRH Antagonist versus GnRH Agonist Protocol on ART outcomes in Poor ovarian Responders

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201302271760N21
Enrollment
100
Registered
2013-08-28
Start date
2013-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poor ovarian Responders. Other ovarian dysfunction

Interventions

Intervention 1: Intervention group: Agonist (3-2 days after onset of LD cycles lasting 21-14 days, take one tablet daily for 21 days and the cycle Busereline 500 µg (Super facts) will subcutaneously.
Treatment - Drugs
Intervention group: Agonist (3-2 days after onset of LD cycles lasting 21-14 days, take one tablet daily for 21 days and the cycle Busereline 500 µg (Super facts) will subcutaneously. Later down regu
Control group: Antagonist (GnRH when the follicle diameter 10mm, reach to daily injections of HCG, Cetrorelix 0.25 mg subcutaneously daily will)

Sponsors

Vice Chancellor for Research and Technology, Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
37 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Infertile women who underwent IVF process and poor ovarian response; The number of oocytes recovered in less than 5; Serum estradiol levels on the day of HCG injection is less than pg / ml 600; Serum FSH levels in Male than 3 mIU / ml 12; Has over 37 years of age; Cessation of ovarian cycles due to poor response. Exclusion criteria: Chronic diseases; Diabetes; Any endocrine disease; Submucosal polyps; Leiomyoma and uterine septum.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pregnancy. Timepoint: 7-6 weeks to see the gestational sac. Method of measurement: Ultrasound.

Secondary

MeasureTime frame
Endometrial thickness. Timepoint: Day of HCG injection. Method of measurement: Ultrasound.;Estradiol levels. Timepoint: Day of HCG injection. Method of measurement: Ultrasound.;The number of oocytes recovered. Timepoint: Day puncture. Method of measurement: Laboratory.;The duration of ovarian stimulation. Timepoint: Duration of drug use. Method of measurement: Clinical.;No. of fertilized oocytes. Timepoint: Day of embryo transfer. Method of measurement: Laboratory.;The amount of transferred embryos. Timepoint: Day of embryo transfer. Method of measurement: Laboratory.;The number of canceled cycles. Timepoint: Before embryo transfer. Method of measurement: Clinical.;Pregnancy than to transfer. Timepoint: 16 days after embryo transfer. Method of measurement: Laboratory.;The incidence of ovarian hyperstimulation syndrome (OHSS). Timepoint: After puncture. Method of measurement: Clinical & Laboratory.;The total amount of FSH. Timepoint: 48 hours before puncture. Method of measurement: Laboratory.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNargess Gholizadeh Pasha

Fatemehzahra Fertility & reproductive Health Reseach Center

ngh_pa@yahoo.com+98 11 1227 4881

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026